Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Determinants of Erythropoietin Hyporesponsiveness in Management of Anemia in Hemodialysis Patients

혈액투석 환자의 빈혈관리에서 Erythropoietin 반응에 영향을 미치는 인자

  • Shin, Seung-Hee (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Ji, Eun-Hee (College of Pharmacy, Seoul National University) ;
  • Lee, Young-Sook (College of Pharmacy, Institute of Pharmaceutical Research and Development, Wonkwang University) ;
  • Oh, Jung-Mi (College of Pharmacy, Seoul National University)
  • Received : 2011.02.12
  • Accepted : 2011.04.13
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Although recombinant human erythropoietin (rhEPO) has revolutionized the treatment of anemia in chronic kidney disease (CKD) receiving hemodialysis (HD) with no need of blood transfusion, some patients have a blunted or appear to be resistant to rhEPO. There is a controversy in the causes of rhEPO resistance in maintenance HD patients with anemia. This study is to examine current anemia treatment outcomes and the factors influencing the rhEPO responsiveness in HD patient with CKD. Methods: The clinical parameters or factors relating to erythrompoietin treatment outcomes and erythropoietin responsiveness were collected from the HD patients in two large dialysis centers for three months. The collected paramenters included serum iron, total iron biding capacity (TIBC), transferrin saturation rate, ferritin, albumin, intact PTH, C-reactive protein (CRP), nPCR and medications such as an angiotensin converting enzyme inhbitor, an angiotension II receptor blocker and an HMG-CoA reductase inhibitor (HMG-CoA RI). The data were analyzed to examine the degree of acheiveing the anemia treatment goal and factors relating to ERI. Results: Among total 111 patients, 42 (42.3%) and 47 (37.8%) patients achieved the target Hct and Hb based on the Health Insurance Review and Assessment Services (HIRA) reimbursement criteria. In the higher ERI group (upper quartile), the patients had higher CRP levels (0.5 mg/dl) (p=0.0096), and lower TIBC score (<$240{\mu}g/dl$) (p=0.0027), and less patients were taking HMG-CoA RI (p=0.0019). Male patients (p=0.0204), patients with high TIBC score ($R^2$=0.084, p=0.0021) and patients taking HMG-CoA RI (p=0.0052) required to administer less dose of rhEPO meaning higher erythropoietin responsiveness. Conclusion: Less than 50% of CKD patients were achieving the goals of anemia by erythropoietin administration in large hospitals in Korea even though the goals were lower than those of NKF-K/DOQI practice guideline. The factors influencing ERI were sex, TIBC and HMG-CoA RI administration status, and neither an ACEI nor an ARB did not influence ERI.

Keywords

References

  1. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int 1985; 28: 1-5. https://doi.org/10.1038/ki.1985.109
  2. Coladonato JA, Frankenfield Dl, Reddan DN et al., Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002; 13: 1288-1295. https://doi.org/10.1097/01.ASN.0000013294.11876.80
  3. 김성남, 최규복. 혈액투석 환자에서 투석 적절도와 빈혈과의 관계. 대한신장학회지 2003; 22(4): 420-425.
  4. IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37(1 Suppl 1): S182-238. https://doi.org/10.1016/S0272-6386(01)70008-X
  5. Miyake T, Kung CK-H, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252(15): 5558- 5564 .
  6. Jacobs K, Shoemaker C, Rudersdorf R et al., Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-810. https://doi.org/10.1038/313806a0
  7. 송현용, 윤향숙, 강신욱 et al., 말기 신부전 환자에서 투여 경로에 따른 유전자 재조합 인 Erhthropoietin ($Epokine^{(R)}$) 의 효과와 안정성에 대한 연구. 대한신장학회지 2002; 21(2): 190-198.
  8. Gregory N. Quality of life in patients on dialysis: Benefits of maintaining a hemoglobin of 11 to 12 g/dL. Nephrol Nurs J 2005; 32(3): 307- 310.
  9. 건강보험심사평가원 홈페이지. http://www.hira.or.kr/ (최종 방문일 2009/11/25)
  10. Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? Nephrol Dial Transplant 2002; 17 (Suppl 5): 2-7.
  11. Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 1997; 10: 607-614.
  12. Tonelli M, Blake PG, Muirhead N. Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 2001; 47: 82-85. https://doi.org/10.1097/00002480-200101000-00017
  13. Ifudu O, Uribarri J, Rajwani I. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis 2000; 36(6): 1166-74. https://doi.org/10.1053/ajkd.2000.19830
  14. Albitar S, Genin R, Fen-Chong M, Serveaux M-O, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-1210. https://doi.org/10.1093/ndt/13.5.1206
  15. Abu-Alfa AK, Cruz D, Perazella MA et al., ACE Inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am J Kidney Dis 2000; 35: 1076-1082. https://doi.org/10.1016/S0272-6386(00)70043-6
  16. Odabas AR, Cetinkaya R, Selccuk Y, Keles S, Bilen H. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med 2003; 45(1): 59-62.
  17. Sirken G, Kung SC, Raja R. Decreased erythropoeitin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 2003; 49(4):422-5.
  18. Muhammd S. Jeffery Leiser, Bruce A. Erythropoietin require-ments increase following hospitalization in end-stage renal disease patients. Am J Nephrol 2001; 21: 390-396. https://doi.org/10.1159/000046281
  19. 김성남, 최규복. 혈액투석 환자에서 투석 적절도와 빈혈과의 관계. 대한신장학회지 2003; 22(4): 420-425.
  20. 권건호, 황경화, 김경수. 혈액투석 환자에서 Erythropoietin 저항성에 영향을 미치는 인자 -혈액투석 환자에서 EPO 저항성. 대한내과학회지 2000; 58(5): 510-515.
  21. 조종태, 박영선. 혈액투석 치료를 받고 있는 말기신부전 환자에서 적혈구생성인자에 치료반응이 불량한 환자들의 임상적 특징. 대한신장학회지 2004; 23(1): 128-137.
  22. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al., Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42; 761-773.
  23. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72. https://doi.org/10.1016/S0272-6386(99)70259-3
  24. Gejyo F, Saito A, Akizawa T et al., 2004 Japanese society for dialysis therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004; 8(6):443-459. https://doi.org/10.1111/j.1774-9987.2004.00199.x
  25. Ifudu O, Urivarri J, Rajwani I et al., Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis 2001; 38(3): 518-522. https://doi.org/10.1053/ajkd.2001.26842
  26. Di Iorio BR, Stellato D, De Santo NG, Cirillo M. Association of gender and age with erythropoietin resistance in hemodialysis patients: Role of menstrual status. Blood Purif 2004; 22: 423-427. https://doi.org/10.1159/000080234
  27. Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004; 43(3): 471-478. https://doi.org/10.1053/j.ajkd.2003.11.008
  28. Zelichowski G, Olszowska A, Lubas A, Walkowicz Z. Influence of parathormone level on the doses of human recombinant erythropoietin in haemodialysed patients. Pol Merkuriusz Lek 2002; 13(77): 373 abstract.